Ulcerative colitis is a chronic inflammatory bowel disease characterized by persistent mucosal inflammation extending from the rectum into the proximal colon. Vitamin D plays a role in regulating immune responses in several inflammatory and autoimmune diseases. Also, studies in animal models have shown that vitamin D supplementation plays a role in the treatment of inflammatory bowel diseases. Thus, this study aims to investigate the role of vitamin D in ulcerative colitis patients.

This study was a case-control type and 4 groups of people were included in this study. Group 1: People with ulcerative colitis who have responded to treatment (24 Persons). Group 2: A family member of responded to treatment patients who does not have the disease (24 Persons). Group 3: People with ulcerative colitis who have not responded to treatment (23 Persons). Group 4: A family member of treatment-resistant patients who do not have the disease(23 Persons).Blood samples were taken from the patients and analyzed for complete blood count (CBC), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP). Enzyme-linked immunosorbent assay (ELISA) was used to measure serum vitamin D levels.

In this study, the age; mean (std. dev.) in the group ulcerative colitis who have responded to treatment was 45.88 (18.51) and in the group ulcerative colitis who have not responded to treatment was 41.30 (13.01). Vitamin D; mean (std. dev.) in the group ulcerative colitis who have responded to treatment was 24.96 (9.66) ng/mg and in the group ulcerative colitis who have not responded to treatment was 27.70 (12.28) ng/mg, showing that there is no significant difference in terms of serum vitamin D.

In this study, there was no significant association between ulcerative colitis and serum vitamin D levels. Therefore, in our study, the serum level of vitamin D has no role in the pathogenesis and treatment of ulcerative colitis patients.